Company Overview and News

 
Foreign outflow from the CSE $ 10mn on the day, $ 50mn for 2018

2018-10-15 lankabusinessonline
October 15, 2018 (LBO) – Foreign outflow out of the Sri Lankan stock market topped Rs1.7bn (US$10mn) on the day as the former owner of Singer Sri Lanka (SINS) disposed of their last 9.47% stake in the company.
SINS JKELF JKH JKEHY

 
Block trade in Singer Sri Lanka (SINS), 9.47% of outstanding shares traded at Rs47

2018-10-15 lankabusinessonline
October 15, 2018 (LBO) – The Colombo Stock Exchange woke up today with a block trade in Singer Sri Lanka. 35,562,883 shares traded at Rs47, up sharply from the previous days’s closing price of around Rs30/share.
SINS

 
Hayleys celebrates 140 years of innovative excellence in Sri Lanka

2018-08-13 lankabusinessonline
Leading Sri Lankan multinational and diversified conglomerate, Hayleys PLC celebrates 140 years of business excellence and innovation this year.
SINS

 
Fitch affirms Sri Lanka-based retailer Abans at ‘BBB+(lka)’ with stable outlook

2018-08-06 lankabusinessonline
Fitch Ratings has affirmed Sri Lanka-based retailer Abans PLC’s (Abans) National Long-Term Rating at ‘BBB+(lka)’ with a Stable Outlook. A full list of rating action is at the end of this commentary.
AFSL SINS

 
Bathiya and Santhush appointed brand ambassadors for Sony audio products in Sri Lanka

2018-07-30 lankabusinessonline
Singer (Sri Lanka) PLC, the country’s premier consumer durables retailer, together with Sony International, has appointed Sri Lanka’s leading musical duo Bathiya and Santhush (BNS) as brand ambassadors for Sony audio products in the country.
SINS

 
Fitch rates Singer Sri Lanka’s proposed debenture ‘A- (lka)(EXP)’

2018-07-20 lankabusinessonline
Jul 20, 2018 (LBO) – Fitch Ratings has assigned Singer (Sri Lanka) PLC’s (A- (lka)/Stable) proposed senior unsecured redeemable debenture issue of up to LKR1.5 billion an expected National Long-Term Rating of ‘A-(lka)(EXP)’.
SINS SFIN SUN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CSE:SINS / SINGER SRI LANKA PLC on message board site Silicon Investor.

Cousins Properties Inc. (CUZ) Cousins Properties Inc. (CUZ) Cousins Properties Inc. (CUZ) Confess your sins here. Confess your sins here. Confess your sins here.